Literature DB >> 29398283

Hospitalizations due to exacerbations of COPD: A big data perspective.

Xavier Serra-Picamal1, Ramon Roman1, Joan Escarrabill2, Anna García-Altés1, Josep Maria Argimón3, Nestor Soler4, Rosa Faner5, Elisenda Martinez Carbonell1, Antoni Trilla6, Alvar Agusti7.   

Abstract

BACKGROUND: Patients with Chronic Obstructive Pulmonary Disease (COPD) may suffer episodes of exacerbation (ECOPD) that require hospitalization and worsen their health status, and prognosis. We hypothesized that a detailed interrogation of health-care "big data" databases can provide valuable information to better understand the risk factors and outcomes of these episodes.
MATERIAL AND METHODS: We interrogated four databases of the Catalan health-care system (>8,000,000 registries) to identify patients hospitalized because of ECOPD for the first time (index event) between 2010 and 2012. Analysis was carried forward since the index event until the end of 2014 or the death of the patient. The two years that preceded the index event were also investigated.
RESULTS: We identified 17,555 patients, (≥50 years of age) hospitalized because of ECOPD (ICD9 v.9 codes at discharge) for the first time between 2010 and 2012. In this population we observed that: (1) 23% of patients die within a year after being discharged from their first ECOPD hospitalization; (2) in the remaining patients, all-cause mortality was related to the number of re-hospitalizations, particularly with early (<30 days) readmissions; (3) despite this being a 'respiratory' cohort, prescription and dispensation of drugs for cardiovascular diseases was higher than for obstructive airway diseases; and, finally, (4) lower winter ambient temperatures are associated with hospital admissions for ECOPD particularly in early re-admitters.
CONCLUSIONS: Overall these results indicate under appreciation of the burden of COPD in patients hospitalized for the first time because ECOPD.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Chronic bronchitis; Emphysema; Epidemiology; Exacerbations; Hospitalizations

Mesh:

Year:  2018        PMID: 29398283     DOI: 10.1016/j.rmed.2018.01.008

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  6 in total

1.  Treatment strategies after acute exacerbations of chronic obstructive pulmonary disease: Impact on mortality.

Authors:  Fernando Casas-Mendez; Maria Jose Abadías; Oriol Yuguero; Ignasi Bardés; Ferran Barbé; Jordi de Batlle
Journal:  PLoS One       Date:  2018-12-14       Impact factor: 3.240

Review 2.  Nanotherapeutics to Modulate the Compromised Micro-Environment for Lung Cancers and Chronic Obstructive Pulmonary Disease.

Authors:  Dhruv R Seshadri; Anand Ramamurthi
Journal:  Front Pharmacol       Date:  2018-07-16       Impact factor: 5.810

3.  Chronic obstructive pulmonary disease (COPD) in Spain and the different aspects of its social impact: a multidisciplinary opinion document.

Authors:  E Bouza; A Alvar; P Almagro; T Alonso; J Ancochea; F Barbé; J Corbella; D Gracia; E Mascarós; J Melis; M Miravitlles; M Pastor; P Pérez; D Rudilla; A Torres; J B Soriano; A Vallano; F Vargas; E Palomo
Journal:  Rev Esp Quimioter       Date:  2020-01-14       Impact factor: 1.553

4.  eHealth Program to Reduce Hospitalizations Due to Acute Exacerbation of Chronic Obstructive Pulmonary Disease: Retrospective Study.

Authors:  Amanda R van Buul; Caroline Derksen; Ouke Hoedemaker; Oscar van Dijk; Niels H Chavannes; Marise J Kasteleyn
Journal:  JMIR Form Res       Date:  2021-03-18

5.  Real-life burden of hospitalisations due to COPD exacerbations in Spain.

Authors:  José Luis Izquierdo; José Miguel Rodríguez; Carlos Almonacid; María Benavent; Ramón Arroyo-Espliguero; Alvar Agustí
Journal:  ERJ Open Res       Date:  2022-08-15

6.  Baseline low ALT activity is associated with increased long-term mortality after COPD exacerbations.

Authors:  N Lasman; M Shalom; N Turpashvili; G Goldhaber; Y Lifshitz; E Leibowitz; G Berger; G Saltzman-Shenhav; A Brom; D Cohen; C Avaky; G Segal
Journal:  BMC Pulm Med       Date:  2020-05-11       Impact factor: 3.317

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.